SLG
SUPN icon

Stanley-Laman Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Stanley-Laman Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-124,000
Closed -$5.34M – 210
2017
Q2 		$5.34M Sell
124,000
-3,481
-3% -$124K 1.45% 11
2017
Q1 		$3.99M Buy
127,481
+15,908
+14% +$426K 1.08% 25
2016
Q4 		$2.82M Buy
+111,573
New +$2.49M 0.87% 23

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Stanley-Laman Group's SUPN Position: Q3 2017 in Review

Stanley-Laman Group sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 124,000 shares — an estimated $5.34M sold.

Stanley-Laman Group first reported a position in SUPN in Q4 2016 and held it in 3 quarters. The position peaked at $5.34M in Q2 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Stanley-Laman Group reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Stanley-Laman Group sold 124,000 Supernus Pharmaceuticals shares in Q3 2017, an estimated $5.34M.
  • Stanley-Laman Group first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Stanley-Laman Group's Supernus Pharmaceuticals position peaked at $5.34M in Q2 2017.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Stanley-Laman Group's 13F filing for Q3 2017, filed 13 Nov 2017.